Intra-Cellular Therapies: A Dramatic Story [Seeking Alpha]
Vanda Pharmaceuticals Inc. (VNDA)
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=196233&p=irol-irhome
Company Research
Source: Seeking Alpha
francescoch/iStock via Getty ImagesI last addressed Intra-Cellular (NASDAQ:ITCIRainbowThis is my firstrevisit of the name. I remain positive as I discuss below.Expect good things from Intra-Cellular's CAPLYTACAPLYTA (lumateperone) was first approved by the FDA in 12/2019 for treatment of adults with schizophrenia. It joined acrowded10-KNet revenues from product sales consist of sales of CAPLYTA, which was approved by the FDA on December 2019. We initiated the commercial launch of CAPLYTA in late March 2020 and generated approximately $22.5 million in net revenue from product sales for the year ended December 31, 2020. During this product launch year, 2020 net sales increased steadily from approximately $883,000 in the first quarter of 2020 to approximately $12.4 million in the fourth quarter.Things got much more interesting with FDA's 12/2021 approval for CAPLYTA in treatment of bipolar depression in adults. Intra-Cellular promptly launched CAPLYTA in its newly approved indication. Re
Show less
Read more
Impact Snapshot
Event Time:
VNDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNDA alerts
High impacting Vanda Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VNDA
News
- Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda PharmaceuticalsGlobeNewswire
- Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Vanda (VNDA) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]Yahoo! Finance
- Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation [Yahoo! Finance]Yahoo! Finance
VNDA
Earnings
- 2/7/24 - Beat
VNDA
Analyst Actions
- 2/9/24 - TheStreet
VNDA
Sec Filings
- 4/17/24 - Form 8-A12B
- 4/17/24 - Form 8-K
- 4/3/24 - Form 8-K
- VNDA's page on the SEC website